Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 3,042 | 388 | 37 | 83 | 143 |
| Gross Profit | 3,042 | 388 | 37 | 83 | 143 |
| Operating Expenses | 56,296 | 59,045 | 50,476 | 48,566 | 46,598 |
| Operating Income | -53,254 | -58,657 | -50,439 | -48,483 | -46,455 |
| Other Income | 7,528 | 5,701 | 5,182 | 5,369 | 6,212 |
| Pre-tax Income | -45,726 | -52,956 | -45,257 | -43,114 | -40,243 |
| Net Income Continuous | -46,026 | -52,956 | -45,257 | -43,114 | -40,243 |
| Net Income | $-46,026 | $-52,956 | $-45,257 | $-43,114 | $-40,243 |
| EPS Basic Total Ops | -1.13 | -1.41 | -1.25 | -1.21 | -1.34 |
| EPS Basic Continuous Ops | -1.13 | -1.41 | -1.25 | -1.21 | -1.34 |
| EPS Diluted Total Ops | -1.13 | -1.41 | -1.25 | -1.21 | -1.34 |
| EPS Diluted Continuous Ops | -1.13 | -1.41 | -1.25 | -1.21 | -1.34 |
| EPS Diluted Before Non-Recurring Items | -1.14 | -1.41 | -1.25 | -1.21 | N/A |
| EBITDA(a) | $-52,922 | $-58,343 | $-50,133 | $-48,206 | $-46,208 |